Kelsey Moody

Moody demonstrates a durable professional commitment to translating aging biology into drug development, but the evidence does not contain a concrete destination, timeline, theory of change, or explicit vision for ending aging, reversing decline, or substantially extending healthy human lifespan.

Moody has credible, independently corroborated scientific impact, anchored by an h-index of 10, 728 citations, and participation in a highly cited Cell study connecting SIRT6-mediated DNA repair with longevity. The citation record is meaningful but concentrated in one paper, and his relatively minor authorship position makes his individual contribution and agenda-setting influence unclear.

Capital deployment is relevant to Moody's entrepreneurial role, but the supplied evidence identifies no investments, donations, catalytic positions, or credible investees reaching human trials. His scientific publications do not demonstrate capital-deployment impact.

Moody shows a coherent strategy of integrating aging-mechanism research with therapeutic development, and his longevity involvement dates back at least to a 2010 regenerative-medicine call to action. His participation in influential SIRT6 research also aligns with that thesis. However, the evidence does not identify specific early or contrarian deployment decisions, demonstrate that vertical integration opened otherwise neglected paths, or support a strong counterfactual claim about his strategic choices.

Independent academic sources confirm that Ichor Therapeutics existed as a longevity-focused research organization and produced collaborative research, but the supplied evidence does not independently establish Moody as its founder or demonstrate that he created broader programs, communities, categories, or funding paths. The dimension applies, but the documented field-building achievement is limited.

The dimension applies, but the supplied record provides little direct evidence of public risk-taking or exceptional conviction. Moody's 2010 call to action for medical students in regenerative medicine suggests an early public commitment to a then-emerging field, and his sustained longevity-focused research indicates continuity. However, there is no documented career sacrifice, major personal financial bet, persistence under serious criticism, self-experimentation, or clearly contrarian public stance.

Moody shows modest second-order leverage through widely cited collaborative research and an early field-organizing call to action, but the evidence does not establish substantial attraction of talent, capital, founders, policy attention, or follow-on ventures.